Clinical Trials

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms

NCT03844048 2026-03-20

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

165 enrolled

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02952508 2026-03-18

CLOVER-WaM

120 enrolled

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Phase 1/2 Recruiting

130 enrolled

Multiple Myeloma, Neoplasms

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1/2 Recruiting

440 enrolled

Multiple Myeloma, Neoplasms

NCT05650632 2026-02-12

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

210 enrolled

Multiple Myeloma, Neoplasms

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

39 enrolled 15 charts

Phase 1 Active not recruiting

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT05259839 2025-12-19

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

283 enrolled

Multiple Myeloma, Neoplasms

NCT03287908 2025-10-08

A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

174 enrolled

Phase 1/2 Active not recruiting

Multiple Myeloma, Neoplasms

NCT03162536 2025-09-08

ARQ 531-101

190 enrolled

LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Active not recruiting

156 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT05308654 2025-08-14

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

34 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms

NCT05286229 2025-08-08

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

8 enrolled

Multiple Myeloma, Neoplasms

NCT05153330 2025-07-03

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

55 enrolled

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Disease Progression, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

265 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT01946477 2025-06-06

POM MM 014

186 enrolled

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Phase 1/2 Terminated

103 enrolled 21 charts

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT03061305 2025-01-31

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Terminated

58,213 enrolled

Phase 2 Active not recruiting

Lymphoma, Multiple Myeloma, Neoplasms

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

73 enrolled

BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Phase 1/2 Completed

169 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04028479 2024-12-18

ROOT

Completed

167 enrolled

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidMyeloidNETOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Nasopharyngeal Carcinoma, Adenocarcinoma, Adrenal Gland Neoplasms, Anus Neoplasms, Appendiceal Neoplasms, Astrocytoma, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoid Tumor, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Chondrosarcoma, Colonic Neoplasms, Carcinoma, Adenoid Cystic, Esophageal Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liposarcoma, Liver Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Melanoma, Mesothelioma, Multiple Myeloma, Neoplasms, Multiple Endocrine Neoplasia, Neoplasms, Unknown Primary, Ovarian Neoplasms, Pancreatic Neoplasms, Parathyroid Neoplasms, Parotid Neoplasms, Penile Neoplasms, Pharyngeal Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Skin Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Ureteral Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Central Nervous System Neoplasms, Cholangiocarcinoma, Carcinoma, Small Cell, Neuroendocrine Tumors, Brain Stem Neoplasms, Gestational Trophoblastic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01943851 2024-10-01

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

111 enrolled 71 charts

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT02099539 2024-09-26

QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma

19 enrolled 22 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT02978235 2024-09-05

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

11 enrolled

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

189 enrolled

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT01183949 2024-08-02

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Phase 1/2 Completed

18 enrolled

Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Phase 1 Recruiting

81 enrolled

NCT01670994 2024-06-18

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

6 enrolled 10 charts

Classical hematologyGenitourinaryHead & NeckLymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT05635266 2024-05-07

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Recruiting

20,000 enrolled

red meat allergy, Alopecia Areata, Alzheimer Disease, Amyloidosis, Anemia, Sickle Cell, Arthritis, Asthma, Autistic Disorder, Behcet Syndrome, Celiac Disease, Colitis, Ulcerative, Crohn Disease, Cystic Fibrosis, Dermatitis, Atopic, Diabetes Mellitus, Epilepsies, Myoclonic, Fibrosis, Fibromyalgia, Graves Disease, Heart Diseases, Hepatitis, Hypersensitivity, Kidney Diseases, Leukemia, Lupus Erythematosus, Systemic, Lymphoma, Macular Degeneration, Multiple Sclerosis, Myasthenia Gravis, Neoplasms, Parkinson Disease, Pemphigus, Psoriasis, Schizophrenia, Spondylitis, Ankylosing, Thyroid Diseases, Vasculitis, Vitiligo, beta-Thalassemia, Hidradenitis Suppurativa, Hepatitis, Autoimmune, Stroke, Pulmonary Disease, Chronic Obstructive, Scleroderma, Diffuse

NCT00457782 2024-04-25

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

27 enrolled

Bronchiolitis Obliterans Syndrome, Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, B-Cell, Lymphoma, B-Cell

NCT02157636 2024-04-18

A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

30 enrolled

Multiple Myeloma, Neoplasms

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

4 enrolled

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT01421524 2023-12-12

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

CNSGastrointestinalLymphoidPlasma cell

271 enrolled

Carcinoma, Glioblastoma, Carcinoma, Hepatocellular, Lymphoma, Multiple Myeloma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

206 enrolled 40 charts 4 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT01348919 2023-06-28

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

11 enrolled 15 charts

Multiple Myeloma, Neoplasms

NCT03445663 2023-03-07

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

27 enrolled

Multiple Myeloma, Neoplasms

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

8 enrolled

Multiple Myeloma, Neoplasms, Recurrence

NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Phase 1 Unknown

29 enrolled

Other hematologic neoplasmPlasma cellSarcoma

NCT01345019 2022-11-08

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Phase 3 Completed

1,718 enrolled 22 charts

Blood Protein Disorders, Bone Diseases, Bone Marrow Diseases, Bone Neoplasms, Hematologic Diseases, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Paraproteinemias, Spinal Cord Compression, Hematologic Neoplasms, Fractures, Bone, Neoplasms, Plasma Cell

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

6 enrolled 19 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT01353625 2021-10-05

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

CNSGenitourinaryHead & NeckLymphoidOther hematologic neoplasmPlasma cell

118 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Glioblastoma, Leukemia, Lymphoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01723020 2021-09-02

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

107 enrolled

CNSPlasma cell

Glioblastoma, Multiple Myeloma, Neoplasms

NCT02177682 2021-08-11

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

9 enrolled

Multiple Myeloma, Neoplasms

NCT04178902 2021-07-26

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

8 enrolled

BreastGenitourinaryLymphoidPlasma cellThoracic

Multiple Myeloma, Neoplasms, Recurrence

NCT03351140 2021-07-14

Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function

Completed

1 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Follicular, Multiple Myeloma, Neoplasms, Prostatic Neoplasms

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

8 enrolled 12 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

NCT01742286 2020-06-09

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

CNSLymphoidPlasma cellSarcoma

83 enrolled 30 charts

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies